Eli Lilly and CoHAM:LLY +4.02%98 Days Inventory is 358.40 as of Mar. 2026, which is 43% above its 10-year median of 251.46. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,239.15 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 916 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 90.28% on this metric.
The historical rank and industry rank for Eli Lilly and Co's Days Inventory or its related term are showing as below:
HAM:LLY'
s Days Inventory Range Over the Past 10 Years
Min: 196.31 Med: 251.46 Max: 357.67
Current: 357.67
During the past 13 years, Eli Lilly and Co's highest Days Inventory was 357.67. The lowest was 196.31. And the median was 251.46.
HAM:LLY's Days Inventory is ranked worse than 90.28% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs HAM:LLY: 357.67
Eli Lilly and Co's Days Inventory
increased
from Mar. 2025 (351.59) to Mar. 2026 (358.40).
It might indicate that Eli Lilly and Co's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Eli Lilly and Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.25.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Eli Lilly and Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.71.
Eli Lilly and Co (HAM:LLY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Eli Lilly and Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Eli Lilly and Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Eli Lilly and Co Days Inventory Related Terms
Eli Lilly and Co Days Inventory Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:LLY vs JNJ, ABBV, MRK: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (HAM:LLY) has a Days Inventory of 358.40 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Eli Lilly and Co and its competitors. This is 43% above median its historical median of 251.46. Over the past decade, Eli Lilly and Co's Days Inventory has ranged from 196.31 to 357.67. According to the industry distribution chart, Eli Lilly and Co ranks #827 out of 916 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is Eli Lilly and Co's Days Inventory too high?
Eli Lilly and Co's current Days Inventory of 358.40 is 43% above median its 10-year median of 251.46. Over the past 10 years, this metric has ranged from a low of 196.31 to a high of 357.67. The Drug Manufacturers industry median Days Inventory is 164.43. Eli Lilly and Co's value of 358.40 is 118% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #827 out of 916 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Days Inventory compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #827 out of 916 companies for Days Inventory. This places Eli Lilly and Co in the lower half of its industry. The industry median Days Inventory is 164.43. Eli Lilly and Co's value of 358.40 is 118% above this benchmark. Historically, Eli Lilly and Co's own Days Inventory has ranged from 196.31 to 357.67 over the past decade. While the company's 10-year median is 251.46 vs. the industry median of 164.43, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Days Inventory of 358.40 is 118% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Days Inventory is 358.40, which is 43% above median its own 10-year median of 251.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,239.15, compared to a current price of €1,081.20 — trading 12.7% below its estimated fair value. The current Days Inventory is 358.40, which is 43% above median its 10-year median of 251.46 and 118% above the Drug Manufacturers industry median of 164.43. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Days Inventory is 358.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €1,081.20 is trading 12.7% below its estimated GF Value™ of €1,239.15.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for HAM:LLY:
Days Inventory: 358.40 (43% above median its 10-year median of 251.46)
GF Value™: €1,239.15 vs. price of €1,081.20 (12.7% below fair value)
Industry Position: 118% above the Drug Manufacturers median (#827 of 916)
No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for HAM:LLY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:LLY has been successfully added to your 
